RichardFrancisRiedelMD

Oncology • Durham, NC

Associate Professor, Division of Medical Oncology, Department of Medicine, Duke University Medical Center

Join to view full profile

Dr. Riedel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Riedel's full profile

Already have an account?

Office
Campus Box 3841
Dumc
Durham, NC 27710
Phone+1 919-684-8111

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2003 - 2007
Duke University HospitalResidency, Internal Medicine, 2000 - 2003
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000

Certifications & Licensure

NC State Medical License 2000 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia Start of enrollment: 2012 Apr 01
Terminated
Phase 1
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Start of enrollment: 2014 Jul 01
Completed
Phase 2
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Start of enrollment: 2019 Feb 08
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities.
Laura H Rosenberger, Richard F Riedel, Emilia J Diego, Amanda L Nash, Juneko E Grilley-Olson
The Oncologist. 2024-12-06
Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board.
Ajay Gupta, Matthew S Dietz, Richard F Riedel, Aditi Dhir, Scott C Borinstein
Cancer. 2024-12-01
Diagnosis and management of dedifferentiated liposarcoma: A multidisciplinary position statement.
Candace L Haddox, Jason L Hornick, Christina L Roland, Elizabeth H Baldini, Vicki L Keedy
Cancer Treatment Reviews. 2024-12-01

Journal Articles

The Experiences of Older Caregivers of Cancer Patients Following Hospital Discharge
Richard F Riedel, Ellen Mahoney, Thomas W LeBlanc, Cristina C Hendrix, Supportive care in cancer

Lectures

A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SAR...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Is There an Optimal Treatment Sequence for Systemic Therapy in Metastatic Disease?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Press Mentions

Empowering Community Cancer Providers: Resources for Sarcoma CareDecember 19th, 2024
Bad to the Bone: Emerging Approaches to Aggressive Bone SarcomasMay 1st, 2023
Epizyme’s Sarcoma Drug Sails Through FDA Panel with Unanimous VoteDecember 18th, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member